Drug Trial Radar · NCT05723588
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 31, 2023
Primary completion
Nov 1, 2027
Study completion Nov 1, 2027
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Feb 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tobacco use is the number one preventable cause of the death in the United States, and is high among US Veterans, and those who have experienced trauma are more likely to smoke. Despite the efficacy of current evidence-based treatments for smoking cessation, there is a critical need for alternative treatments. This project seeks to evaluate the feasibility and effectiveness of a smoking cessation treatment for Veterans with posttraumatic stress disorder (PTSD) who smoke. The treatment combines smoking cessation counseling, nicotine replacement therapy (e.g., nicotine gum), and repetitive transcranial magnetic stimulation (rTMS). rTMS is a noninvasive brain stimulation treatment that has been cleared by the Food and Drug Administration for smoking cessation in adults.
Conditions
- Tobacco Use Disorder
Interventions
active repetitive transcranial magnetic stimulationDevice
Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.
sham repetitive transcranial magnetic stimulationDevice
Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.
cognitive behavioral therapy for smoking cessationBehavioral
All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.
nicotine replacement therapyDrug
All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a "rescue" method such as nicotine lozenge or nicotine gum.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility as measured by number of participants recruitedTime frame: At consent
- Feasibility as measured by the percent of participants who complete the studyTime frame: 3-month follow-up
- Number of participants with self-reported and bioverified abstinence from smokingTime frame: End of treatment, about five weeks after beginning study
- Number of participants with self-reported and bioverified abstinence from smokingTime frame: 3-month follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Durham VA Medical Center, Durham, NC
Durham, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.